| Purpose: Objectively evaluate the clinical efficacy and safety of Shenqi Dihuang Decoction in the treatment of chronic glomerulonephritis with deficiency of both qi and yin and damp-heat and blood stasis,and explore the treatment of chronic glomerulonephritis by means of modern network pharmacology The mechanism of action of Shenqi Dihuang Decoction provides clinical evidence for the treatment of chronic glomerulonephritis.Material and Method:1.Clinical effect observation of Shenqi Dihuang Decoction in the treatment of chronic glomerulonephritis with deficiency of qi and yin combined with damp-heat and blood stasis.The retrospective research method was used to collect the medical records of 65 patients with Qi-Yin deficiency combined with damp-heat and blood stasis type who visited the outpatient department of Professor Ma Xiaoyan,Department of Nephrology,Liaoning University of Traditional Chinese Medicine from September 2019 to September 2021.A total of 65 cases were set up in the observation group(38 cases).Conventional treatment + Huangkui Capsules,Huaiqihuang Granules + Shenqi Dihuang Decoction),27 cases in the control group(conventional treatment + Huangkui Capsules,Huaiqihuang Granules),the course of treatment was 8 weeks,and the 24-hour urine protein was observed before and after treatment.Quantitative,urine sediment red blood cell count(RBC),liver and kidney function(ALT,AST,BUN,Scr,e GFR)and other safety indicators,as well as TCM symptom change data,were summarized and sorted,and compared using statistical methods.2.The network pharmacology study of Shenqi Dihuang Decoction in the treatment of chronic glomerulonephritis.The active small molecule active ingredients of Shenqi Dihuang Decoction and the corresponding corresponding targets were searched in TCMSP database,and OB≥30% and DL≥0.18 were set as the screening conditions to screen the active ingredients.The obtained target information was matched in the Uniprot database to obtain the corresponding target gene.The chronic glomerulonephritis-related disease genes were retrieved from the Genecards database,and the intersecting genes obtained by intersecting the drug genes with the disease genes were input into the String database for PPI network construction.Finally,the intersecting genes were input into the Metascape website for GO function analysis and KEGG enrichment.set analysis.Results:1 Clinical observation of Shenqi Dihuang decoction in the treatment of chronic glomerulonephritis with deficiency of both qi and yin combined with damp-heat and blood stasis(1)Comparison within the group: the 24-hour urine protein quantification and urine sediment red blood cell count in the observation group after treatment were significantly reduced compared with those before treatment,with significant statistical difference(P<0.01);Compared with before,it was statistically significant(P<0.05).The urine sediment red blood cell count after treatment was not statistically significant compared with before treatment(P>0.05).(2)Comparison between groups: The 24-hour urine protein quantification and urine sediment red blood cell count in the observation group were significantly different from those in the control group(P<0.01).(3)Syndrome score: After treatment,the syndrome score of the observation group was significantly lower than that before treatment,with a statistical difference(P<0.01),and was significantly better than that of the control group(P<0.01).(4)There was no statistical significance in the comparison of safety indexes before and after treatment between the two groups(P>0.05),and the index values were all within the normal range,indicating that the two groups of treatment programs were safe and reasonable.2 Network pharmacology study of Shenqi Dihuang decoction in the treatment of chronic glomerulonephritis(1)88 active small molecule components and 235 target genes were retrieved and screened by TCMSP database.(2)After screening by cytoscape,it was concluded that quercetin,β-sitosterol,kaempferol,stigmasterol and isorhamnetin were in the center of the network.(3)A total of 1788 chronic glomerulonephritis-related genes were retrieved from the Genecards database,and 895 corresponding genes were obtained after the median of the relevance score was screened.(4)The PPI network was constructed through the STRING database,and a total of 98 nodes were obtained.After screening,JUN(transcription factor AP-1),PRKCA(protein kinase C alpha type),ESR1(estrogen receptor),HIF1A(hypoxia-induced factor 1-α)and other 29 core targets.(5)According to the KEGG enrichment analysis,the modified Shenqi Dihuang Decoction can participate in the treatment of chronic glomerulonephritis mainly by regulating multiple pathways such as HIF-1 signaling pathway and NF-KB signaling pathway.Conclusion:1 Clinical observation of Shenqi Dihuang decoction in the treatment of chronic glomerulonephritis with deficiency of both qi and yin combined with damp-heat and blood stasis(1)Modified Shenqi Dihuang Decoction combined with Huangkui Capsules and Huaiqihuang Granules can significantly reduce 24-hour urine protein quantification and urine sediment red blood cell count.(2)Modified Shenqi Dihuang Decoction combined with Huangkui Capsules and Huaiqihuang Granules uses nourishing qi and nourishing yin,clearing heat and removing dampness,promoting blood circulation and removing blood stasis.The effective rate is 94.73%,and it is safe and effective.2 Network pharmacology study of Shenqi Dihuang decoction in the treatment of chronic glomerulonephritis(1)Modified Shenqi Dihuang Decoction acts on multiple targets such as JUN,PRKCA,ESR1,HIF1 A,etc.Dot gene,inhibit inflammatory response,and treat chronic glomerulonephritis.(2)Modified Shenqi Dihuang Decoction participates in the treatment of chronic glomerulonephritis by regulating multiple pathways such as HIF-1 signaling pathway and NF-KB signaling pathway,with the characteristics of multi-component,multi-target and multi-pathway synergy. |
PDF Full Text Request